Cancer Vaccines: Technologies and Global Markets

Published - Nov 2016| Analyst - Shalini Shahani Dewan| Code - PHM173B
Cancer Vaccines: Technologies and Global Markets
Single User License: $2,750 Member Price: FREE

Report Highlights

The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021.

Report Includes

  • An overview of the global markets and technologies for cancer vaccines.
  • Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of CAGRs through 2021.
  • Coverage of the cancer vaccines arena including diverse therapeutic platform technologies, immune-stimulating agents and approved vaccines for cancer.
  • Examination of the governmental and regulatory environment and how its effecting the market.
  • Information on new developments including products in Phase I-IV clinical trials, as well as new technologies.
  • Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.
  • Relevant patent analysis, presented by year and by vaccine type.
  • Profiles of major players in the industry.

SCOPE OF THE STUDY

The scope of this study entails the global market of cancer vaccines. The report covers the total market of cancer vaccines, which includes two main areas of applications, prophylactic vaccines and therapeutic vaccines. Human papillomavirus (HPV) vaccines and hepatitis B vaccines that indirectly act against cancer are also included in the report.

The report also covers the global market of cancer vaccines by application in various cancer types such as prostate, liver, cervical and others such as lung and urinary bladder. It is discussed from both a commercial perspective and that of a research and development (R&D) perspective.

BCC Research analyzes each market and its application, regulatory environment, new products and advancements, market projections and market shares. Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis and geographically sales are broken down into North America, Europe and emerging markets. The emerging market covers countries such as India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada among others.

Analysis of patents, clinical trials, innovations and opportunities the latest trends in the cancer vaccine market and comprehensive profiles of companies that lead the cancer vaccine industry are also discussed.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Jan-2015| Analyst - Shalini Shahani Dewan| Code - PHM173A

Report Highlights

The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019.

Report Includes

  • An overview of the global markets and technologies for cancer vaccines.
  • Analyses of global market trends, with data from 2012 and 2013, estimates for 2014, and projections of CAGRs through 2019.
  • Coverage of the cancer vaccines arena including diverse therapeutic platform technologies, immune-stimulating agents and approved vaccines for cancer.
  • Examination of the governmental and regulatory environment and how its effecting the market.
  • Information on new developments including products in Phase I-IV clinical trials, as well as new technologies.
  • Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.
  • Relevant patent analysis, presented by year and by vaccine type.

Want to Customize this Report?

Contact us for a confidential discussion.

781-205-2433

Custom Report
RELATED REPORTS
Share This Report